Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab.

Abstract

Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conventional agents and developed hypotension after rituximab but achieved lasting remission after a single dose of the anti-IgE monoclonal antibody omalizumab.

• Authors: Surabhi Sinha, Diksha Agrawal, Kabir Sardana, Anita Kulhari, Purnima Malhotra
• Journal: Indian dermatology online journal (Indian Dermatol Online J) 2020 Jul-Aug Vol. 11 Issue 4 Pg. 607-611 ISSN: 2229-5178 [Print] India
• PMID: 32832453 (Publication Type: Case Reports)
• Copyright: Copyright: © 2020 Indian Dermatology Online Journal.